Content about Pneumococcal polysaccharide vaccine

February 26, 2013
RxAlly, Shenandoah University pharmacy school collaborate in pneumococcal vaccination study

A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

LEESBURG, Va. — A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

January 28, 2013
FDA approves new use of Pfizer vaccine

The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

NEW YORK — The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

Pfizer announced the approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for children and adolescents ages 6 years to 17 years for active immunization against the 13 Streptococcus pneumonia serotypes the vaccine covers. For this group, Prevnar 13 is administered as a one-time dose to patients who have never received it.

October 15, 2012
New recommendations out for pneumococcal vaccine in high-risk adults

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ACIP now recommends the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13) for high-risk adults ages 19 years or older. The committee recommends that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), the vaccine currently recommended for these groups of adults.

September 4, 2012
Navarro Discount Pharmacy expands adult vaccine offerings

In light of new Florida regulations allowing certified pharmacists to administer a broader range of immunizations, Navarro Discount Pharmacy has expanded vaccine availability at all of its 31 locations in south Florida to include immunizations for both shingles and pneumonia, in addition to the flu vaccine.

MIAMI and PEMBROKE PINES, Fla. — In light of new Florida regulations allowing certified pharmacists to administer a broader range of immunizations, Navarro Discount Pharmacy has expanded vaccine availability at all of its 31 locations in south Florida to include immunizations for both shingles and pneumonia, in addition to the flu vaccine.

January 3, 2012
FDA approves Prevnar 13 in older adults

The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

NEW YORK — The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single-dose for adults.